In a multinomial model, with breast cancers defined by ER status alone, current use (versus never use) was significantly associated with the ER+ (aOR = 2.04, 95%CI: 1.28–3.24), but not the ER- breast cancers (aOR = 1.40, 95%CI: 0.64–3.05). The gene discussed is ESR1; the disease is breast carcinoma.